生物製藥 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "生物製藥" in Chinese language version.

refsWebsite

Global rank Chinese rank

24web.archive.org

1^st place

10doi.org

2^nd place

23^rd place

8nih.gov

4^th place

5^th place

4europa.eu

68^th place

209^th place

3fda.gov

447^th place

581^st place

3archive.org

6^th place

4^th place

2govinfo.gov

1,998^th place

5,642^nd place

1naer.edu.tw

4,367^th place

148^th place

1lexico.com

1,242^nd place

3,795^th place

1nature.com

234^th place

227^th place

1worldcat.org

5^th place

12^th place

1elsevier.com

610^th place

388^th place

1jmcp.org

low place

1nytimes.com

7^th place

31^st place

1washington.edu

1,067^th place

1,375^th place

1rheumatologynetwork.com

low place

1briskfox.com

low place

1investopedia.com

1,135^th place

852^nd place

1researchgate.net

120^th place

337^th place

1federalregister.gov

2,474^th place

3,822^nd place

1thomson.com

low place

1phrma.org

low place

1forbes.com

54^th place

88^th place

1spermdonorsaustralia.com.au

low place

1wur.nl

8,218^th place

low place

1bbc.co.uk

8^th place

32^nd place

1cov.com

low place

1canada.ca

1,712^th place

3,316^th place

archive.org

Rader RA. (Re)defining biopharmaceutical. Nature Biotechnology. July 2008, 26 (7): 743–51. PMID 18612293. doi:10.1038/nbt0708-743 .
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnology. April 2011, 29 (4): 310–2. PMID 21478841. doi:10.1038/nbt.1839 .
Dove A. Milking the genome for profit. Nature Biotechnology. October 2000, 18 (10): 1045–8. PMID 11017040. doi:10.1038/80231.

bbc.co.uk

news.bbc.co.uk

Go-ahead for 'pharmed' goat drug. BBC News. 2006-06-02 [2006-10-25]. （原始内容存档于2007-01-21）.

briskfox.com

BriskFox Financial. Biopharmaceutical sector sees rising R&D despite credit crunch, finds analysis. [2009-03-11]. （原始内容存档于2018-10-03）.

canada.ca

Biologics and Genetic Therapies Directorate. [2019-01-20]. （原始内容存档于2020-10-21）.

cov.com

Kingham R, Klasa G, Carver K. Key Regulatory Guidelines for the Development of Biologics in the United States and Europe (PDF). John Wiley & Sons, Inc. 2014: 75–88 [11 April 2018]. （原始内容存档 (PDF)于2021-08-02）.

doi.org

Walsh, Gary. Biopharmaceutical benchmarks 2018. Nature Biotechnology. 2018, 36 (12): 1136–1145 [2021-08-05]. ISSN 1087-0156. doi:10.1038/nbt.4305 . （原始内容存档于2021-11-24）（英语）.
Ryan, Michael P.; Walsh, Gary. Veterinary-based biopharmaceuticals. Trends in Biotechnology. 2012, 30 (12): 615–620. doi:10.1016/j.tibtech.2012.08.005 （英语）.
Rader RA. (Re)defining biopharmaceutical. Nature Biotechnology. July 2008, 26 (7): 743–51. PMID 18612293. doi:10.1038/nbt0708-743 .
Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND. Health plan utilization and costs of specialty drugs within 4 chronic conditions. Journal of Managed Care Pharmacy. September 2013, 19 (7): 542–8. PMID 23964615. doi:10.18553/jmcp.2013.19.7.542.
Calo-Fernández B, Martínez-Hurtado JL. Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals. December 2012, 5 (12): 1393–408. PMC 3816668 . PMID 24281342. doi:10.3390/ph5121393.
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnology. April 2011, 29 (4): 310–2. PMID 21478841. doi:10.1038/nbt.1839 .
Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy. April 2018, 18 (4): 369–379. PMID 29285958. doi:10.1080/14712598.2018.1421169 .
Nick C. The US Biosimilars Act: Challenges Facing Regulatory Approval. Pharm Med. 2012, 26 (3): 145–152 [2012-06-13]. doi:10.1007/bf03262388.
Decker EL, Reski R. Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess and Biosystems Engineering. January 2008, 31 (1): 3–9. PMID 17701058. doi:10.1007/s00449-007-0151-y.
Dove A. Milking the genome for profit. Nature Biotechnology. October 2000, 18 (10): 1045–8. PMID 11017040. doi:10.1038/80231.

elsevier.com

linkinghub.elsevier.com

Ryan, Michael P.; Walsh, Gary. Veterinary-based biopharmaceuticals. Trends in Biotechnology. 2012, 30 (12): 615–620. doi:10.1016/j.tibtech.2012.08.005 （英语）.

europa.eu

ema.europa.eu

European Medicines Agency, tooltip definition of advanced therapy medicinal products, Committee for Advanced Therapies (CAT), [2017-05-15], （原始内容存档于2017-11-15）.
European Medicines Agency, Advanced therapy medicinal products: Overview, [2017-05-15], （原始内容存档于2021-12-19）.
EMA. Questions and answers on biosimilar medicines (similar biological medicinal products) (PDF). European Medicines Agency. 2008-10-30 [2014-10-11]. （原始内容存档 (PDF)于2017-03-15）.

ec.europa.eu

The Commission of the European Communities. Commission Directive 2003/63/EC amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (PDF). Official Journal of the European Union: L 159/62. 2003-06-25 [2021-08-05]. （原始内容存档 (PDF)于2020-10-19）.

fda.gov

存档副本. [2022-11-06]. （原始内容存档于2022-11-06）.
Drugs@FDA Glossary of Terms. Food and Drug Administration. 2 Feb 2012 [8 April 2014]. （原始内容存档于2017-12-07）.
Center for Biologics Evaluation and Research. What is a biological product?. U.S. Food and Drug Administration. 2010-04-01 [2014-02-09]. （原始内容存档于2017-12-07）.

federalregister.gov

75 FR 61497; United States Food and Drug Administration. Approval Pathway for Biosimilar and Interchangeable Biological Products (PDF). Public Hearing; Request for Comments. 2010-10-05 [2021-08-05]. （原始内容存档 (PDF)于2021-09-30）.

forbes.com

Carlyle, Erin. The Guys Who Trade Your Blood For Profit. [2016-09-29]. （原始内容存档于2022-01-10）.

govinfo.gov

United States Food and Drug Administration. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule (PDF). Federal Register. August 2008, 73 (164): 49603–10 [2021-08-05]. PMID 18958946. （原始内容存档 (PDF)于2021-03-01）.
75 FR 61497; United States Food and Drug Administration. Approval Pathway for Biosimilar and Interchangeable Biological Products (PDF). Public Hearing; Request for Comments. 2010-10-05 [2021-08-05]. （原始内容存档 (PDF)于2021-09-30）.

investopedia.com

存档副本. [2021-08-05]. （原始内容存档于2022-01-02）.

jmcp.org

Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND. Health plan utilization and costs of specialty drugs within 4 chronic conditions. Journal of Managed Care Pharmacy. September 2013, 19 (7): 542–8. PMID 23964615. doi:10.18553/jmcp.2013.19.7.542.

lexico.com

Biological. Oxford Dictionaries. [2021-08-05]. （原始内容存档于2021-11-24）.

naer.edu.tw

terms.naer.edu.tw

http://terms.naer.edu.tw/detail/5448943/^{[失效連結]}

nature.com

Walsh, Gary. Biopharmaceutical benchmarks 2018. Nature Biotechnology. 2018, 36 (12): 1136–1145 [2021-08-05]. ISSN 1087-0156. doi:10.1038/nbt.4305 . （原始内容存档于2021-11-24）（英语）.

nih.gov

ncbi.nlm.nih.gov

Rader RA. (Re)defining biopharmaceutical. Nature Biotechnology. July 2008, 26 (7): 743–51. PMID 18612293. doi:10.1038/nbt0708-743 .
Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND. Health plan utilization and costs of specialty drugs within 4 chronic conditions. Journal of Managed Care Pharmacy. September 2013, 19 (7): 542–8. PMID 23964615. doi:10.18553/jmcp.2013.19.7.542.
United States Food and Drug Administration. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule (PDF). Federal Register. August 2008, 73 (164): 49603–10 [2021-08-05]. PMID 18958946. （原始内容存档 (PDF)于2021-03-01）.
Calo-Fernández B, Martínez-Hurtado JL. Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals. December 2012, 5 (12): 1393–408. PMC 3816668 . PMID 24281342. doi:10.3390/ph5121393.
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnology. April 2011, 29 (4): 310–2. PMID 21478841. doi:10.1038/nbt.1839 .
Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy. April 2018, 18 (4): 369–379. PMID 29285958. doi:10.1080/14712598.2018.1421169 .
Decker EL, Reski R. Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess and Biosystems Engineering. January 2008, 31 (1): 3–9. PMID 17701058. doi:10.1007/s00449-007-0151-y.
Dove A. Milking the genome for profit. Nature Biotechnology. October 2000, 18 (10): 1045–8. PMID 11017040. doi:10.1038/80231.

nytimes.com

Thomas, Kate; Pollack, Andrew. Specialty Pharmacies Proliferate, Along With Questions. New York Times. Sinking Spring, Pa. 15 July 2015 [5 October 2015]. （原始内容存档于2019-02-25）.

phrma.org

Growth and Policies Behind Biopharmaceutical Innovation. phrma.org. PhRMA. [11 April 2018]. （原始内容存档于2021-11-24）.

researchgate.net

Nick C. The US Biosimilars Act: Challenges Facing Regulatory Approval. Pharm Med. 2012, 26 (3): 145–152 [2012-06-13]. doi:10.1007/bf03262388.

rheumatologynetwork.com

Kerr LD. The use of biologic agents in the geriatric population. J Musculoskel Med. 2010, 27: 175–180 [2021-08-05]. （原始内容存档于2021-01-27）.

spermdonorsaustralia.com.au

Sperm Donors Australia | Donate Sperm. spermdonorsaustralia.com.au. [2016-09-29]. （原始内容存档于2021-10-28）.

thomson.com

scientific.thomson.com

Foster, Luke. Patenting in the Biopharmaceutical Industry—comparing the US with Europe. [2006-06-23]. （原始内容存档于2006-03-16）.

washington.edu

courses.washington.edu

Murphy CO. Specialty Pharmacy Managed Care Strategies (PDF). [24 September 2015]. （原始内容存档于2018-09-29）.

web.archive.org

Biological. Oxford Dictionaries. [2021-08-05]. （原始内容存档于2021-11-24）.
Walsh, Gary. Biopharmaceutical benchmarks 2018. Nature Biotechnology. 2018, 36 (12): 1136–1145 [2021-08-05]. ISSN 1087-0156. doi:10.1038/nbt.4305 . （原始内容存档于2021-11-24）（英语）.
存档副本. [2022-11-06]. （原始内容存档于2022-11-06）.
Drugs@FDA Glossary of Terms. Food and Drug Administration. 2 Feb 2012 [8 April 2014]. （原始内容存档于2017-12-07）.
Thomas, Kate; Pollack, Andrew. Specialty Pharmacies Proliferate, Along With Questions. New York Times. Sinking Spring, Pa. 15 July 2015 [5 October 2015]. （原始内容存档于2019-02-25）.
Murphy CO. Specialty Pharmacy Managed Care Strategies (PDF). [24 September 2015]. （原始内容存档于2018-09-29）.
European Medicines Agency, tooltip definition of advanced therapy medicinal products, Committee for Advanced Therapies (CAT), [2017-05-15], （原始内容存档于2017-11-15）.
European Medicines Agency, Advanced therapy medicinal products: Overview, [2017-05-15], （原始内容存档于2021-12-19）.
Center for Biologics Evaluation and Research. What is a biological product?. U.S. Food and Drug Administration. 2010-04-01 [2014-02-09]. （原始内容存档于2017-12-07）.
United States Food and Drug Administration. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule (PDF). Federal Register. August 2008, 73 (164): 49603–10 [2021-08-05]. PMID 18958946. （原始内容存档 (PDF)于2021-03-01）.
Kerr LD. The use of biologic agents in the geriatric population. J Musculoskel Med. 2010, 27: 175–180 [2021-08-05]. （原始内容存档于2021-01-27）.
BriskFox Financial. Biopharmaceutical sector sees rising R&D despite credit crunch, finds analysis. [2009-03-11]. （原始内容存档于2018-10-03）.
存档副本. [2021-08-05]. （原始内容存档于2022-01-02）.
EMA. Questions and answers on biosimilar medicines (similar biological medicinal products) (PDF). European Medicines Agency. 2008-10-30 [2014-10-11]. （原始内容存档 (PDF)于2017-03-15）.
75 FR 61497; United States Food and Drug Administration. Approval Pathway for Biosimilar and Interchangeable Biological Products (PDF). Public Hearing; Request for Comments. 2010-10-05 [2021-08-05]. （原始内容存档 (PDF)于2021-09-30）.
Foster, Luke. Patenting in the Biopharmaceutical Industry—comparing the US with Europe. [2006-06-23]. （原始内容存档于2006-03-16）.
Growth and Policies Behind Biopharmaceutical Innovation. phrma.org. PhRMA. [11 April 2018]. （原始内容存档于2021-11-24）.
Carlyle, Erin. The Guys Who Trade Your Blood For Profit. [2016-09-29]. （原始内容存档于2022-01-10）.
Sperm Donors Australia | Donate Sperm. spermdonorsaustralia.com.au. [2016-09-29]. （原始内容存档于2021-10-28）.
Phillip B. C. Jones. European Regulators Curdle Plans for Goat Milk Human Antithrombin (PDF). [2006-06-23]. （原始内容存档 (PDF)于2020-10-20）.
Go-ahead for 'pharmed' goat drug. BBC News. 2006-06-02 [2006-10-25]. （原始内容存档于2007-01-21）.
The Commission of the European Communities. Commission Directive 2003/63/EC amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (PDF). Official Journal of the European Union: L 159/62. 2003-06-25 [2021-08-05]. （原始内容存档 (PDF)于2020-10-19）.
Kingham R, Klasa G, Carver K. Key Regulatory Guidelines for the Development of Biologics in the United States and Europe (PDF). John Wiley & Sons, Inc. 2014: 75–88 [11 April 2018]. （原始内容存档 (PDF)于2021-08-02）.
Biologics and Genetic Therapies Directorate. [2019-01-20]. （原始内容存档于2020-10-21）.

worldcat.org

Walsh, Gary. Biopharmaceutical benchmarks 2018. Nature Biotechnology. 2018, 36 (12): 1136–1145 [2021-08-05]. ISSN 1087-0156. doi:10.1038/nbt.4305 . （原始内容存档于2021-11-24）（英语）.

wur.nl

library.wur.nl

Phillip B. C. Jones. European Regulators Curdle Plans for Goat Milk Human Antithrombin (PDF). [2006-06-23]. （原始内容存档 (PDF)于2020-10-20）.